KSQ Therapeutics, Inc is a clinical-stage biotechnology company based in Lexington, MA, specializing in CRISPRomics, a cutting-edge approach to gene editing and therapeutic target discovery. Their innovative CRISPRomics discovery platform enables them to systematically decode the genome and identify optimal gene targets for the treatment of oncology and autoimmune diseases. With a focus on developing breakthrough medicines, KSQ Therapeutics aims to revolutionize the standard of care for patients by rewiring human biology and potentially offering curative treatments for a wide range of human diseases.
Utilizing their proprietary CRISPRomics platform, KSQ Therapeutics is actively engaged in target drug discovery for targeted cancer therapies and immuno-oncology therapies. Their pipeline includes the first-in-class USP1 inhibitor, KSQ-4279, currently in a Phase 1 clinical trial for advanced solid tumors, and their eTIL autologous cell therapy candidates, KSQ-001 and KSQ-004, which have shown promising efficacy in preclinical models for the treatment of solid tumors. With a focus on precision medicine and leveraging the power of CRISPR technology, KSQ Therapeutics is at the forefront of developing transformative therapies with the potential to cure diseases.
Generated from the website